Juva Life Inc. announced their newly revised WCG IRB-approved cannabis patient registry, renamed to the JuLi Registry ('The Registry'). The JuLi Registry is a WCG IRB -approved multi-year study conducted through Juva Life's cannabis research division. The Registry, listed on clinicaltrials.gov, is aimed at amassing one of the world's larger data sets of real-world clinical evidence on the potential health benefits of cannabis.

It enjoys participation from best-in-class cannabis and cannabidiol (CBD) brands, and includes products from CannaCraft, dosist, LEVEL, San Benito Hemp Company, Sunderstorm, and WYLD. Once completed, Juva will have one of the larger data sets of its kind and will be able to leverage the findings in both its nutraceutical wellness, drug development and clinical programs. This real-world observational data, overseen by physicians and other clinicians, will be presented to various regulatory bodies to show the potential therapeutic benefits of cannabis and hemp-derived compounds. The goal of the Registry is to collect data on cannabis formulations, chemical composition, dosing and utilization, and the effectiveness of cannabis products in addressing designated medical concerns.

The study is open to patients over 21 years of age who have the following conditions or symptoms: chronic pain, anxiety, neuropathy, appetite issues, nausea, sleep issues, and menopausal symptoms. Info on products selected, dosing schedules, impact on symptoms and side effects will be collected. Additionally, the Registry will examine patients' use of cannabis in conjunction with other prescription medication, including any discontinuation or reduction of the use of opioids after initiation of cannabis-based medications.